RxDoctor Payments Data

Thomas Lendvay

Pediatric Urology · Seattle, WANPI 1417038779

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $956,592 of the $957,437 with a category attached, or 99.9%. Johnson & Johnson accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $956,592 and has fallen 100.0% since, to $41 in 2025.

$957,437in general payments, 2019–2025

Across 6 payments — averaging $159,573 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$957K
  • Verathon Inc.$800
  • Travere Therapeutics, Inc.$4

What the payments were for

  • Consulting fees$8000%
  • Speaking & faculty fees$956,592100%
  • Food & beverage$410%
  • Education$40%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)4$956,633
Verathon Inc.1$800
Travere Therapeutics, Inc.1$4

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric urology providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Other pediatric urology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →